Eliem to re-prioritize pipeline, reduce workforce by 55% in 1H23

As part of the reorganization, the company will reduce its workforce by approximately 55% in the first half of 2023.The Company will continue its focus on treatments for neuronal excitability disorders, and is retaining its core R&D team, led by Dr. Valerie Morisset, EVP R&D and Chief Scientific Officer. This team will carry on driving ETX-123 development forward and executing on other pipeline opportunities, including other opportunities for the Kv7 Program.